

Sphincter Tear Rate Falling in Vaginal Births

BY BETSY BATES
Los Angeles Bureau

TUCSON, ARIZ. — The rate of anal sphincter laceration during vaginal delivery has declined sharply in recent years, paralleling modifications in obstetric practice, a University of Southern California study revealed.

Anal sphincter laceration occurred in 11.2% of vaginal deliveries at the colossal Los Angeles County/USC Medical Center in 1996, compared with 7.9% in 2004, with about a 6% reduction in risk every year after 1996, reported Dr. Steven Minaglia at the annual meeting of the Society of Gynecologic Surgeons.

"Changes in obstetric practice, such as the increase in cesarean section and the decrease in operative delivery and episiotomy, may have contributed to the dramatic reduction in sphincter laceration," Dr. Minaglia said.

During the time period studied, episiotomies declined from 9% to 8% of vaginal deliveries, vacuum deliveries from 5.1% to 2.9%, and forceps deliveries from 1.7% to 0%. "Of note, the C-section rate went from 18.2% to 32.3%," he said.

The retrospective study assessed characteristics in 1,703 patients who had an anal sphincter laceration and 14,964 who did not have such an injury, for a total of 16,667 singleton vaginal deliveries at greater than 20 weeks of gestation. Younger age, lower parity, and higher birth weight all were associated with a higher likelihood of an anal sphincter laceration.

Other important risk factors independently associated with a laceration included vacuum delivery (odds ratio 3.19), forceps delivery (OR 2.79), episiotomy (OR 1.36), shoulder dystocia (OR 2.03), and gestational age (OR 1.03, about a 4% increased risk for each week of gestation).

Dr. Minaglia, of the division of female pelvic medicine and reconstructive surgery, encouraged a further minimization of modifiable risk factors such as episiotomy and operative delivery to minimize long-term harm associated with sphincter laceration.

A second study presented at the meeting found similar risk factors at the University of New Mexico Hospital in Albuquerque, where episiotomy and operative vaginal delivery rates are 5%-25% lower than national rates.

The case-control study matched 350 women who sustained a third- or fourth-degree anal sphincter laceration to 716 women matched by gestational age and chronologic time of delivery who did not have a laceration.

The risk of an anal sphincter laceration increased with vacuum extraction (OR 5.96), forceps extraction (OR 11.05), and episiotomy (OR 2.34); as well as maternal age (OR 1.09 per year); and infant weight (OR 1.09 per 100 g).

As in the USC study, multiparity was protective, reported Dr. Alana Williams and associates in a poster presentation. ■

Cesarean May Not Avert Levator Ani Injury

BY BETSY BATES
Los Angeles Bureau

TUCSON, ARIZ. — One woman in four suffers neuropathic injury to the levator ani with her first delivery, according to a novel study that used pre- and postpartum concentric needle electromyographic examinations to study muscle function.

Cesarean sections performed during labor were not protective in the study

conducted by Dr. Alison C. Weidner and her associates at Duke University Medical Center and presented at the annual meeting of the Society of Gynecologic Surgeons.

Initial EMG studies were performed on 58 primiparous women in the early third trimester, providing baseline data on muscle function at four separate sites of the levator ani. A quantitative amplitude analysis provided data on muscle function at rest and during moderate

and maximum voluntary contractions.

Information was collected on the subjects' labor and delivery patterns, and follow-up examinations were performed 6 weeks and 6 months post partum.

The mean age of the subjects was 29 years, and their mean body mass index was 25 kg/m².

Evidence of neuropathic injury was seen in 14 (24%) of 58 subjects at the 6-week examination and 17 (29%) of 58 at the 6-month examination, said Dr. Weid-

NEW

Loest

(norethindrone acetate and ethinyl est

A whole new option in contraception



24 days of active 20 mcg EE therapy

Shorter Periods* Fewer bleeding days compared with Loestrin 1/20 (21-day active therapy)

Lighter Periods Lighter flow compared with Loestrin 1/20 (21-day active therapy)

* In a clinical study of 886 women (Loestrin® 24 Fe: n = 705; Loestrin 1/20: n = 181) by cycle 6, women taking Loestrin® 24 Fe averaged 2.7-day periods, compared with a 3.9-day average for women on Loestrin 1/20. Data on file. Warner Chilcott (US), Inc.

Important Safety Information about Loestrin® 24 Fe

Risks with Loestrin® 24 Fe are similar to those with all birth control pills. Most side effects are not serious and those that are occur infrequently. Serious risks, which can be life threatening, include blood clots, stroke, and heart attacks. **Cigarette smoking increases the risk of serious cardiovascular side effects, especially in women over 35. Women who use oral contraceptives are strongly advised not to smoke.** Some women should not use the Pill, including women who have or have had blood clots, certain cancers, or a history of heart attack or stroke, as well as those who are or may be pregnant. **Oral contraceptives do not protect against HIV infection (AIDS) and other sexually transmitted diseases.**

Please see Brief Summary of Full Prescribing Information for Loestrin® 24 Fe on the page following this advertisement.



© 2006 Warner Chilcott (US), Inc.

LOE169X06

May 2006

Printed in USA